MGMT immunoexpression in adamantinomatous craniopharyngiomas

Zuhur, Sayid Shafi; Müslüman, Ahmet Murat; Tanık, Canan; Karaman, Ozcan; Öztürk, Feyza Yener; Özderya, Ayşenur; Özkayalar, Hanife; Aydın, Yunus

doi:10.1007/s11102-011-0297-0

Cited by 7 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of adamantinomatous craniopharyngiomas exhibit zero to minimal expression of O-6 methylguanine DNA methyltransferase (MGMT), which confers a likely positive response to temozolomide treatment, an agent already being used for other brain tumors. 100 Similarly, tamoxifen has been shown to inhibit craniopharyngioma cell proliferation via inhibition of ADAM-like decysin 1 (ADAM-DEC1) expression, which is limited only to adamantinomatous craniopharyngioma cells and not normal brain tissue. 95 Though associated with significant toxicities and pending validation in animal models of craniopharyngioma, both of these drugs may potentially serve as adjuvant therapies for those tumors resistant to radiation or individuals in whom surgery is contraindicated.…”

Section: Future Directionsmentioning

confidence: 99%

Molecular oncogenesis of craniopharyngioma: current and future strategies for the development of targeted therapies

Hussain¹,

Eloy²,

Carmel³

et al. 2013

JNS

View full text Add to dashboard Cite

show abstract

Section: Future Directionsmentioning

confidence: 99%

Molecular oncogenesis of craniopharyngioma: current and future strategies for the development of targeted therapies

Hussain¹,

Eloy²,

Carmel³

et al. 2013

JNS

View full text Add to dashboard Cite

show abstract

“…Rodriguez et al showed that there was no significant correlation between MGMT expression and methylation, and no significant survival difference was observed between patients whose tumours were negative versus those whose tumours were positive for MGMT protein, as ascertained by immunohistochemistry (25). Also, in a study concerning craniopharyngiomas, Zuhur et al suggest that a high proportion of adamantinomatous craniopharyngioma express a low level of MGMT (26). In studies of pituitary adenomas, the expression of MGMT has no associations with the aggressiveness or relapse of pituitary adenomas (27,28).…”

Section: Invasiveness and Nfpamentioning

confidence: 99%

Low 06-Methylguanine-DNA Methytransferase (MGMT) and Pan-Cytokeratin (PAN-CK) Expression via Immunohistochemistry in Pituitary Adenomas

et al. 2017

View full text Add to dashboard Cite

Introduction. Pituitary adenomas (PA) are the third most common intracranial tumors, with an incidence rate of 10-15%. More than half are invasive, infiltrating adjacent structures. The primary objective of this project was to determine whether MGMT expression is associated with the invasiveness of PA. Material and Method. All patients who underwent surgical decompression consecutively between 2007-2012 were included. All data were obtained from the case records. Formalin-fixed paraffin-embedded (FFPE) tissue specimens were stained with hematoxylin and eosin (HE) and then examined via light microscope. Paraffin blocks that lacked necrosis and hemorrhage were chosen for histologic examination. In addition to an immunoprofile battery that consisted of Ki-67 and p53, MGMT, S-100 and Pan-CK were evaluated as well. Results. The subjects included 25 women and 15 men. The mean age was 48.9 ± 14.5 years. Of these, 63% of cases involved the invasion of adjacent structures. Of the PA, 17 (42%) were non-functioning pituitary adenomas (NFPA). There was a statistically significant relationship between the invasiveness and Ki-67, p53, MGMT expression, and prolactinoma. Gonodotropinomas were mostly non-invasive. FPAs presented invasive features more frequently than NFPAs. Pan-CK was positive in GH-secreting adenomas but negative in FSH-and LH-secreting adenomas. Conclusion. Ki-67 and p53 in lower expression level can be used for evaluating invasiveness but not for recurrence. MGMT expression can be a useful IHC indicator for invasiveness. However, Pan-CK cannot be used for invasiveness or aggressiveness.

show abstract

“…(WHO) classification, they often behave as aggressive tumors and cause significant mortality and morbidity (19,32). Malignant transformation of craniopharyngiomas either after radiotherapy or without previous radiotherapy has also been reported (15).…”

Section: Zuhur Ss Et Al: Immunohistochemical Expression Of Erbb2 In mentioning

confidence: 99%

Immunohistochemical expression of erbb2 in adamantinomatous craniopharyngiomas: a possible target for immunotherapy

Zuhur

Tanık²,

Erol³

et al. 2012

Turkish Neurosurgery

Self Cite

View full text Add to dashboard Cite

AIm:To determine the immunohistochemical expression of ErbB2 in adamantinomatous craniopharyngiomas (ACP) and to assess its relationship with nuclear expression of β-catenin in surgically resected human ACP tissue sections and to estimate whether these tumors could be candidates for anti-ErbB2 therapy. mAterIAl and methOds: The ErbB2 and β-catenin immunostaining was performed on paraffin embedded tissue sections of 20 ACP using avidin-biotin-peroxidase complex method. ErbB2 immunoreactivity was interpreted according to the American Society of Clinical Oncology/ College of American Pathologists criterions for breast carcinoma.results: Foci of nuclear reactivity for β-catenin was observed in all ACP tissue specimens mainly concentrated in whorl like arrays of the epithelial cells. Two (10%) of the cases were score 3+ for ErbB2 as demonstrated by strong complete membrane staining. However, the localization of 3+ ErbB2 cells was different from those with nuclear β-catenin immunoreactivity.COnClusIOn: Our preliminary data demonstrate score 3+ staining for ErbB2 in 10% of ACP and different localization of 3+ ErbB2 cells and cells with nuclear β-catenin immunoreactivity. However, because of the small number of cases, further studies with larger samples should be conducted to verify and validate our preliminary data and to determine the effect of ErbB2 protein in ACP cell growth, survival and differentiation.KeywOrds: Adamantinomatous craniopharyngioma, Immunohistochemistry, EGFR, ErbB2, β-catenin ÖZ AmAÇ: Bu çalışmada, cerrahi olarak çıkarılmış insan adamantinomatöz kraniofarengiomalarında ErbB2'nin immünohistokimyasal ekspresyonunu, ErbB2 ekspresyonunun β-katenin ekspresyonu ile ilişkisini ve adamantinomatöz kraniofarengiomaların anti-ErbB2 tedavisine yanıt olasılığını tahmin etmeyi amaçladık. yÖntem ve GereÇler: Çalışmamızda 20 adamantinomatöz kraniofarengiomanın parafin bloklarının kesitleri avdin-biotin-peroksidaz kompleks yöntemi ile boyandı. ErbB2 immünreaktivitesi Amerikan Klinik Onkoloji Derneği/Amerikan Patoloji Koleji'nin meme karsinomu kriterlerine göre değerlendirildi.BulGulAr: Genellikle epitel hücrelerinin oluşturduğu sarmal benzeri yapılarda yoğun olmak üzere nükleer β-katenin immünreaktivite odakları tüm adamantinomatöz kraniofarengiomalarda saptandı. İki (%10) olguda ErbB2 3+ bulundu. Ancak ErbB2 3+ hücreler ile nükleer β-katenin immünreaktif hücrelerin lokalizasyonları farklı idi.sOnuÇ: Bizim ön verilerimiz adamantinomatöz kraniofarengiomaların %10'unda ErbB2'nin 3+ olduğunu ve ErbB2 3+ hücrelerin lokalizasyonunun nükleer β-katenin immünreaktif hücrelerin lokalizasyonundan farklı olduğunu göstermektedir. Bununla birlikte çalışmamız az sayıda olgu içerdiğinden dolayı ön verilerimizin doğrulanması ve ErbB2 proteininin adamantinomatöz kraniofarengioma hücrelerinin büyümesi, sağkalımı ve farklılaşması üzerindeki etkileri daha fazla sayıda olguyu içeren ileri çalışmalarla gösterilmesi gerekmektedir.

show abstract

MGMT immunoexpression in adamantinomatous craniopharyngiomas

Cited by 7 publications

References 23 publications

Molecular oncogenesis of craniopharyngioma: current and future strategies for the development of targeted therapies

Molecular oncogenesis of craniopharyngioma: current and future strategies for the development of targeted therapies

Low 06-Methylguanine-DNA Methytransferase (MGMT) and Pan-Cytokeratin (PAN-CK) Expression via Immunohistochemistry in Pituitary Adenomas

Immunohistochemical expression of erbb2 in adamantinomatous craniopharyngiomas: a possible target for immunotherapy

Contact Info

Product

Resources

About